TW201611834A - Hexahydrofuropyrroles as PDE1 inhibitors - Google Patents
Hexahydrofuropyrroles as PDE1 inhibitorsInfo
- Publication number
- TW201611834A TW201611834A TW104103370A TW104103370A TW201611834A TW 201611834 A TW201611834 A TW 201611834A TW 104103370 A TW104103370 A TW 104103370A TW 104103370 A TW104103370 A TW 104103370A TW 201611834 A TW201611834 A TW 201611834A
- Authority
- TW
- Taiwan
- Prior art keywords
- hexahydrofuropyrroles
- pde1 inhibitors
- pde1
- inhibitors
- medicament
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201400069 | 2014-02-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW201611834A true TW201611834A (en) | 2016-04-01 |
Family
ID=58698416
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW104103370A TW201611834A (en) | 2014-02-07 | 2015-02-02 | Hexahydrofuropyrroles as PDE1 inhibitors |
Country Status (26)
Country | Link |
---|---|
US (1) | US9718832B2 (zh) |
EP (1) | EP3102584B1 (zh) |
JP (1) | JP6532880B2 (zh) |
KR (1) | KR20160115931A (zh) |
CN (1) | CN106414459B (zh) |
AP (1) | AP2016009344A0 (zh) |
AR (1) | AR099300A1 (zh) |
AU (1) | AU2015214214A1 (zh) |
CA (1) | CA2935470A1 (zh) |
CL (1) | CL2016001959A1 (zh) |
CR (1) | CR20160322A (zh) |
DO (1) | DOP2016000179A (zh) |
EA (1) | EA201691335A1 (zh) |
EC (1) | ECSP16071574A (zh) |
ES (1) | ES2711085T3 (zh) |
GE (1) | GEP201706795B (zh) |
HK (1) | HK1232214A1 (zh) |
IL (1) | IL246718A0 (zh) |
MA (1) | MA39230B1 (zh) |
MX (1) | MX2016010168A (zh) |
PE (1) | PE20161071A1 (zh) |
PH (1) | PH12016501495A1 (zh) |
RU (1) | RU2016130684A (zh) |
SG (1) | SG11201606445YA (zh) |
TW (1) | TW201611834A (zh) |
WO (1) | WO2015118097A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3126354T3 (da) * | 2014-04-04 | 2020-03-09 | H Lundbeck As | Halogenerede quinazolin-thf-aminer som pde1-inhibitorer |
KR102590848B1 (ko) | 2016-12-28 | 2023-10-19 | 다트 뉴로사이언스, 엘엘씨 | Pde2 억제제로서 치환된 피라졸로피리미디논 화합물 |
JP7254078B2 (ja) | 2017-11-27 | 2023-04-07 | ダート・ニューロサイエンス・エルエルシー | Pde1阻害剤としての置換フラノピリミジン化合物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060183763A1 (en) * | 2004-12-31 | 2006-08-17 | Pfizer Inc | Novel pyrrolidyl derivatives of heteroaromatic compounds |
PT2057153E (pt) * | 2006-07-10 | 2012-11-14 | Lundbeck & Co As H | Derivados (3-aril-piperazin-1-il) de 6,7- dialcoxiquinazolina, 6,7-dialcoxiftalazina e 6,7-dialcoxiisoquinolina |
JP2011506439A (ja) * | 2007-12-14 | 2011-03-03 | メルク・シャープ・エンド・ドーム・コーポレイション | アルツハイマー病治療のための3,4−置換ピロリジンβ−セクレターゼ阻害剤 |
-
2015
- 2015-02-02 TW TW104103370A patent/TW201611834A/zh unknown
- 2015-02-05 AR ARP150100339A patent/AR099300A1/es unknown
- 2015-02-06 MA MA39230A patent/MA39230B1/fr unknown
- 2015-02-06 US US15/116,743 patent/US9718832B2/en active Active
- 2015-02-06 EP EP15705781.1A patent/EP3102584B1/en active Active
- 2015-02-06 AU AU2015214214A patent/AU2015214214A1/en not_active Abandoned
- 2015-02-06 WO PCT/EP2015/052492 patent/WO2015118097A1/en active Application Filing
- 2015-02-06 RU RU2016130684A patent/RU2016130684A/ru not_active Application Discontinuation
- 2015-02-06 CA CA2935470A patent/CA2935470A1/en not_active Abandoned
- 2015-02-06 ES ES15705781T patent/ES2711085T3/es active Active
- 2015-02-06 SG SG11201606445YA patent/SG11201606445YA/en unknown
- 2015-02-06 CR CR20160322A patent/CR20160322A/es unknown
- 2015-02-06 JP JP2016550614A patent/JP6532880B2/ja active Active
- 2015-02-06 MX MX2016010168A patent/MX2016010168A/es unknown
- 2015-02-06 EA EA201691335A patent/EA201691335A1/ru unknown
- 2015-02-06 GE GEAP201514236A patent/GEP201706795B/en unknown
- 2015-02-06 CN CN201580005675.8A patent/CN106414459B/zh active Active
- 2015-02-06 PE PE2016001246A patent/PE20161071A1/es not_active Application Discontinuation
- 2015-02-06 AP AP2016009344A patent/AP2016009344A0/en unknown
- 2015-02-06 KR KR1020167021342A patent/KR20160115931A/ko not_active Application Discontinuation
-
2016
- 2016-07-11 IL IL246718A patent/IL246718A0/en unknown
- 2016-07-19 DO DO2016000179A patent/DOP2016000179A/es unknown
- 2016-07-28 PH PH12016501495A patent/PH12016501495A1/en unknown
- 2016-08-03 CL CL2016001959A patent/CL2016001959A1/es unknown
- 2016-09-05 EC ECIEPI201671574A patent/ECSP16071574A/es unknown
-
2017
- 2017-06-09 HK HK17105707.4A patent/HK1232214A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
RU2016130684A (ru) | 2018-03-15 |
MX2016010168A (es) | 2016-10-07 |
MA39230B1 (fr) | 2018-04-30 |
ECSP16071574A (es) | 2017-02-24 |
PE20161071A1 (es) | 2016-10-30 |
CN106414459A (zh) | 2017-02-15 |
AU2015214214A1 (en) | 2016-07-14 |
EP3102584A1 (en) | 2016-12-14 |
EP3102584B1 (en) | 2019-01-16 |
CN106414459B (zh) | 2018-08-03 |
CA2935470A1 (en) | 2015-08-13 |
GEP201706795B (en) | 2017-12-11 |
JP2017505328A (ja) | 2017-02-16 |
DOP2016000179A (es) | 2016-09-30 |
CR20160322A (es) | 2016-09-16 |
ES2711085T3 (es) | 2019-04-30 |
US20160347759A1 (en) | 2016-12-01 |
EA201691335A1 (ru) | 2016-12-30 |
AP2016009344A0 (en) | 2016-07-31 |
JP6532880B2 (ja) | 2019-06-19 |
AR099300A1 (es) | 2016-07-13 |
WO2015118097A1 (en) | 2015-08-13 |
KR20160115931A (ko) | 2016-10-06 |
CL2016001959A1 (es) | 2017-02-24 |
IL246718A0 (en) | 2016-08-31 |
US9718832B2 (en) | 2017-08-01 |
HK1232214A1 (zh) | 2018-01-05 |
MA39230A1 (fr) | 2017-07-31 |
SG11201606445YA (en) | 2016-09-29 |
PH12016501495A1 (en) | 2017-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500621A1 (en) | Triazolopyrazinones as pde1 inhibitors | |
PH12017501990A1 (en) | Imidazopyrazinones as pde1 inhibitors | |
GB2541571A (en) | Pharmaceutical compositions | |
PH12016501173A1 (en) | Quinazolin-thf-amines as pde1 inhibitors | |
PH12016501938A1 (en) | Halogenated quinazolin-thf-amines as pde1 inhibitors | |
PH12016501495A1 (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
NZ711523A (en) | Use of sedoheptulose for prevention or treatment of inflammation | |
HUE060927T2 (hu) | N,N-bisz-2-merkaptoetil-izoftálamid neurodegeneratív betegségek kezelésére |